ABOUT THIS CONFERENCE
Once thought to be an irreversible mechanism, our view of histone methylation has changed with the discovery of a new class of druggable enzymes responsible for the removal and maintenance of methyl groups. The past few years have seen much excitement elucidating the functional and therapeutic benefit of modulating genetically aberrant or overexpressed histone demethylase (HDM) enzymes across a selection of diseases. In addition, robust high-throughput screening and hit-finding approaches have progressed, enabling the development of inhibitors, with high activity and potency. Continued efforts require a deepened understanding of the biological consequences of modulation, heightened specificity of screens and hit finding, and ultimately, increased production of small molecule inhibitors for lead development and optimization. The Targeting Histone Demethylases conference will join pharmaceutical, biotech and academic researchers to network, collaborate and discuss practical solutions to challenges, while exploring the expanding arena of HDM therapeutics.
SUGGESTED EVENT PACKAGE:
September 23: Biochemical and Structure-Based Approaches to Epigenetic Drug Discovery Short Course
September 23: Characterization and Quantification of Histone Modifications Short Coursee
September 24 - 25: Targeting Histone Methyltransferases Conference
September 25 - 26: Targeting Histone Demethylases Conference
Targeting the Histone Demethylome
Udo Oppermann, Ph.D., Professor, Molecular Biology; Director, Molecular Laboratory Sciences, Botnar Research Centre; Principal Investigator, Epigenetics and Metabolism, Structural Genomics Consortium, University of Oxford
Targeting Histone Demethylation in Cancer
Ryan Kruger, Ph.D., Manager, Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline Pharmaceuticals
Targeting Lysine-Specific Demethylase 1 with Polyamine Analogues to Induce Expression of Aberrantly Silenced Genes
Robert A. Casero, Jr., Ph.D., Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Reactivation of Repressed Epigenetic Mechanisms with Small Molecule Inhibitors
Michael McCabe, Ph.D., Investigator, Biology, Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline Pharmaceuticals
JARID1 Demethylases as Cancer Targets
Qin Yan, Ph.D., Assistant Professor, Pathology, Yale University School of Medicine
The Therapeutic Potential of Jumonji Histone Demethylase Inhibitors
Peter Staller, Ph.D., Director, Oncology Research, EpiTherapeutics ApS
Chromatin Regulators as Therapeutic Targets in Breast Cancer
Kornelia Polyak, M.D., Ph.D., Associate Professor, Department of Medicine, Harvard Medical School; Associate Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute
Chromatin Modification in Reversible Tolerance to Anti-Cancer Drug
Jeffrey Settleman, Ph.D., Senior Director, Discovery Oncology, Genentech
Epigenetic Therapy for Cancer Treatment
Lorraine Gudas, Ph.D., Chairman & Revlon Pharmaceutical Professor, Pharmacology and Toxicology, Pharmacology Department, Weill Cornell Medical College
Talk Title to be Announced
Igor P. Pogribny, M.D., Ph.D., Principal Research Investigator, Division of Biochemical Toxicology, National Center for Toxicological Research, FDA
Epigenetic Reprogramming in Pancreatic Cancer: The Emerging Role of Histone Demethylases
Alexandros Tzatsos, M.D., Ph.D., Instructor, Medicine, Harvard Medical School; Assistant Geneticist, Massachusetts General Hospital Cancer Center
Targeting H3K9me2 Writers and Erasers
Xiaodong Cheng, Ph.D., Professor of Biochemistry & Georgia Research Alliance Emminent Scholar, Emory University School of Medicine
Strategies for Identifying New Chemical Probes for Histone Lysine Demethylases
Brian Lohse, Ph.D., Associate Professor, Drug Design and Pharmacology, University of Copenhagen
Structure and Specificity of JMJD2 Histone Demethylases
Raymond C. Trievel, Ph.D., Associate Professor of Biological Chemistry, University of Michigan Medical School
Nitric Oxide is an Endogenously Produced Epigenetic Regulatory Molecule
Douglas Thomas, Ph.D., Associate Professor, Medicinal Chemistry, University of Illinois at Chicago